Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of Limnetrelvir
NCT05995366Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of limnetrelvir in coronavirus disease 2019 (COVID-19), sponsored by AbbVie Inc. Primary endpoints: Maximum observed concentration, Time to Cmax and 4 more. Started Aug 2023; status: completed.
02
Drugs
limnetrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05995366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995366.